Literature DB >> 10780333

Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor.

R E Grossmann, U Geisen, S Schwender, F Keller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10780333

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  5 in total

Review 1.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

2.  Desmopressin responsiveness by age in type 1 von Willebrand disease.

Authors:  Nicola Goldberg; Rosane Nisenbaum; Hong Song; David Lillicrap; Jerome Teitel; Paula James; Michelle Sholzberg
Journal:  Res Pract Thromb Haemost       Date:  2020-05-30

3.  Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies.

Authors:  Gianluca Sottilotta; Francesca Luise; Elisabetta Massara; Vincenzo Oriana; Angela Piromalli
Journal:  J Clin Med       Date:  2017-09-18       Impact factor: 4.241

Review 4.  Current and Emerging Options for the Management of Inherited von Willebrand Disease.

Authors:  Jessica M Heijdra; Marjon H Cnossen; Frank W G Leebeek
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 5.  How I manage severe von Willebrand disease.

Authors:  Frank W G Leebeek; Ferdows Atiq
Journal:  Br J Haematol       Date:  2019-09-09       Impact factor: 6.998
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.